Search

Your search keyword '"Corvol, Jean-Christophe"' showing total 982 results

Search Constraints

Start Over You searched for: Author "Corvol, Jean-Christophe" Remove constraint Author: "Corvol, Jean-Christophe"
982 results on '"Corvol, Jean-Christophe"'

Search Results

1. Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases

2. Amantadine use in the French prospective NS-Park cohort

3. The impact of subthalamic deep-brain stimulation in restoring motor symmetry in Parkinson’s disease patients: a prospective study

4. Prognosis of impulse control disorders in Parkinson’s disease: a prospective controlled study

5. Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study

7. Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations

9. Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning

10. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

11. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

12. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

13. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

14. Personality assessment with Temperament and Character Inventory in Parkinson's disease

15. X-vectors: New Quantitative Biomarkers for Early Parkinson's Disease Detection from Speech

16. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

17. Genome-wide determinants of mortality and motor progression in Parkinson’s disease

19. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease

22. Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial

23. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression

24. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

26. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

28. The Progressive Supranuclear Palsy Clinical Deficits Scale

29. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

30. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

33. Association of abnormal explicit sense of agency with cerebellar impairment in myoclonus-dystonia

34. Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty

37. Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study

40. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

41. The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease

42. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

43. Neuro-Psychological Outcome of ICU-Admitted COVID-19 Patients Presenting With CNS Complications

44. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

46. Behavioural disinhibition in frontotemporal dementia investigated within an ecological framework

48. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease

49. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

50. Personalised Medicine ∙ Leveraging the Potential of Digital Technology for Personalised Medicine.

Catalog

Books, media, physical & digital resources